30.06.2013 Views

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

How does the operation of PHARMAC's 'Community Exceptional ...

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

cumbersome and recommended that PHARMAC speed up its decision making<br />

processes. The NZAF was also concerned that with <strong>the</strong> establishment <strong>of</strong> 21<br />

DHBs (replacing one Health Funding Authority), <strong>the</strong>y would have to deal with<br />

many more public agencies to negotiate services and contracts. This would<br />

present <strong>the</strong> NZAF with high and prohibitive transaction costs (PB/ 91 NZ AIDS<br />

Foundation, 2000).<br />

They also complained that <strong>the</strong> cost-utility analysis which has been applied to<br />

HIV/AIDS treatment drugs, only takes into account <strong>the</strong> cost and availability <strong>of</strong><br />

alternative treatments. This economic analysis system used by PHARMAC did<br />

not take into account <strong>the</strong> capacity <strong>of</strong> <strong>the</strong> person or <strong>the</strong> wider costs and benefits<br />

to society <strong>of</strong> having AIDS patients treated with drugs which were effective and<br />

available in o<strong>the</strong>r countries. The NZAF submitted that PHARMAC had been<br />

unwilling to listen to expert advice on <strong>the</strong> effectiveness <strong>of</strong> AIDS medication.<br />

They stated that PHARMAC considered it a virtue that decisions were made by<br />

generalists, despite <strong>the</strong> abundance <strong>of</strong> specialist advice being available to it, and<br />

PHARMAC seemed almost completely unwilling to seek such advice or accept<br />

external expert advice if <strong>of</strong>fered (PB/ 91 NZ AIDS Foundation, 2000).<br />

NZAF made three substantive suggestions to change <strong>the</strong> Bill. Firstly, <strong>the</strong>y<br />

suggested that PHARMAC should give new consideration to decision making in<br />

respect <strong>of</strong> HIV antiretroviral treatments. Secondly, PHARMAC should<br />

incorporate substantially more expert opinion in decision making on HIV<br />

antiretroviral treatments. Finally, <strong>the</strong>y suggested that PHARMAC should ensure<br />

all costs and benefits to society and to <strong>the</strong> individual are taken into account<br />

when a cost-utility analysis is carried out to decide on applications to <strong>the</strong><br />

pharmaceutical schedule (PB/ 91 NZ AIDS Foundation, 2000).<br />

Submission on Complementary Medicines<br />

The New Zealand Charter <strong>of</strong> Health Practitioners Inc. (NZCHP) gave a<br />

submission on behalf <strong>of</strong> its members who practiced complementary health care.<br />

They urged <strong>the</strong> government in <strong>the</strong>ir submission to introduce complementary<br />

health services into <strong>the</strong> public health service and fund complementary health<br />

products through PHARMAC. Specifically, <strong>the</strong> government should facilitate<br />

access to holistic complementary health care and wellness services. They<br />

urged <strong>the</strong> government to provide payments for complementary disability support<br />

127

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!